Toumai SP Single-Port Surgical Robot

Toumai Product Family: Toumai Multi-Port (Standard) | Toumai SP (Single-Port) | Toumai Tele-Robotic (Remote Surgery)

Toumai SP extends MicroPort MedBot’s laparoscopic platform with a specialized single-port configuration, enabling complex abdominal procedures through a single 2.5cm umbilical incision. The system received NMPA market approval in March 2025 (registration no. 20253010347), becoming China’s second domestically developed single-port surgical robot.

Product Overview

Building on the established Toumai platform, the SP variant addresses growing clinical demand for single-incision surgery that minimizes visible scarring. The system employs a novel mechanical architecture where three snake-shaped instruments and a snake-shaped endoscope converge through a single port positioned at the umbilicus.

The design emphasizes adaptability to space-constrained environments, with a compact footprint suitable for operating rooms that cannot accommodate larger multi-port systems. This positions Toumai SP for deployment in facilities where physical space limitations have previously prevented surgical robot adoption.

Key Features

Toumai SP is MicroPort MedBot’s single-port laparoscopic robot, routing three snake-shaped instruments and a flexible endoscope through one 2.5cm umbilical incision for virtually scarless abdominal surgery.

• Single-Port Design: All instruments access the surgical field through one 2.5cm incision at the umbilicus, resulting in virtually scarless surgery
• Snake-Shaped Instruments: Flexible, articulated instruments navigate around each other within the confined entry point
• Compact Footprint: Reduced system size improves compatibility with smaller operating rooms
• High Adjustability: Mechanical design accommodates varied patient anatomies and surgical approaches
• Integrated Endoscope: Dedicated snake-shaped camera provides visualization through the single port

Technical Specifications

Approved by NMPA in March 2025 for urology, general surgery, and gynecology, Toumai SP delivers a compact footprint and multi-segment articulation via a single 2.5cm umbilical access point.

Clinical Applications

Toumai SP received NMPA approval for clinical use across urology, general surgery, and gynecology departments. The single-port approach offers particular advantages for:

Urology: Nephrectomy, partial nephrectomy where cosmetic outcomes are prioritized General Surgery: Cholecystectomy, appendectomy in patients desiring minimal scarring Gynecology: Hysterectomy, oophorectomy with concealed incision

The system is particularly suited for procedures where cosmetic results significantly impact patient satisfaction, such as surgery in younger patients or those with concerns about visible scarring.

Regulatory Status

As MicroPort MedBot’s newest surgical robot platform, international regulatory submissions are expected to follow the domestic approval.

Design Innovation

The single-port configuration presents significant engineering challenges in terms of instrument collision avoidance and coordinated motion control. MicroPort’s solution employs highly integrated mechanical design that manages the geometric constraints of multiple articulated instruments sharing a common entry point.

The snake-shaped instrument architecture differs fundamentally from traditional rigid laparoscopic tools, requiring specialized control algorithms to translate surgeon inputs into appropriate multi-segment articulation patterns.

Frequently Asked Questions

How is Toumai SP different from the standard Toumai?

Toumai SP performs surgery through a single 2.5cm incision at the belly button rather than multiple port sites. This results in essentially invisible scarring but requires specialized snake-shaped instruments to navigate through the single access point.

What are the advantages of single-port surgery?

Single-port surgery minimizes visible scarring by using a concealed umbilical incision. Patients may experience reduced postoperative pain and faster cosmetic recovery compared to multi-port approaches.

Is Toumai SP available outside China?

As of early 2025, Toumai SP has received NMPA approval for the Chinese market only. International regulatory submissions are anticipated based on MicroPort MedBot’s established globalization strategy.